Securities Registration: Employee Benefit Plan (s-8)
May 11 2021 - 5:11PM
Edgar (US Regulatory)
As filed with the U.S. Securities and Exchange Commission on May 11, 2021
Registration No. 333-
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Taysha Gene Therapies, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
Delaware
|
|
84-3199512
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
3000 Pegasus Park Drive
Suite 1430
Dallas, Texas
75247
(Address of principal executive offices)(Zip code)
Taysha Gene Therapies, Inc. 2020 Stock Incentive Plan
(Full title of the plan)
RA Session II
President
and Chief Executive Officer
Taysha Gene Therapies, Inc.
3000 Pegasus Park Drive
Suite 1430
Dallas, Texas
75247
(214) 612-0000
(Name and address of agent for service)(Telephone number, including area code, of agent for service)
Copies to:
|
Divakar Gupta
Madison Jones
Brian F.
Leaf
Darren DeStefano
Cooley LLP
55 Hudson
Yards
New York, NY 10001
Telephone: (212) 479-6000
Facsimile: (212) 479-6275
|
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer
|
|
☐
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
Non-accelerated filer
|
|
☒
|
|
Smaller reporting company
|
|
☒
|
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☒
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
CALCULATION
OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Title of Securities to be Registered
|
|
Amount
to be
Registered(1)
|
|
Proposed
Maximum
Offering
Price
per Share
|
|
Proposed
Maximum
Aggregate
Offering Price
|
|
Amount of
Registration Fee
|
Common Stock, par value $0.00001 per share 2020 Stock
Incentive Plan
|
|
1,434,934 (2)
|
|
$21.01 (3)
|
|
$30,147,963.34
|
|
$3,289.15
|
Total
|
|
1,434,934
|
|
|
|
$30,147,963.34
|
|
$3,289.15
|
|
|
(1)
|
Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the
Securities Act), this Registration Statement shall also cover any additional shares of Registrants common stock that become issuable under the plans set forth herein by reason of any stock dividend, stock split,
recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrants common stock.
|
(2)
|
Represents an automatic increase equal to 3.8% of the total number of shares of the Registrants
capital stock outstanding on December 31 of the preceding calendar year to the aggregate number of shares of the Registrants common stock reserved for issuance under the Registrants 2020 Stock Incentive Plan (as amended, the
2020 Plan), which increase was determined by the Compensation Committee of the Board of Directors of the Company pursuant to the 2020 Plan.
|
(3)
|
Estimated in accordance with Rule 457(c) and (h) solely for purposes of calculating the
registration fee on the basis of $21.01, the average of the high and low prices of the Registrants common stock as reported on the Nasdaq Global Select Market on May 10, 2021.
|
REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E
Pursuant to General Instruction E of Form S-8, Taysha Gene Therapies, Inc. (the
Registrant) is filing this Registration Statement with the Securities and Exchange Commission (the Commission) to register 1,434,934 additional shares of its common stock under the 2020 Plan,
pursuant to the provisions of the 2020 Plan providing for an automatic increase in the number of shares of common stock reserved and available for issuance under the 2020 Plan on January 1, 2021. In accordance with the instructional note to
Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.
The contents of the Registrants Registration Statement on Form S-8 (File No. 333-249130), filed with the Commission on September 29, 2020, are incorporated by reference into this Registration Statement.
PART II
Item 3
|
Incorporation of Certain Documents by Reference
|
The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:
(a) The Registrants Annual Report on Form
10-K for the fiscal year ended December 31, 2020 filed with the Commission on March 3, 2021;
(b) The Registrants Quarterly Report on Form
10-Q for the quarter ended March 31, 2021 filed with the Commission on May 11, 2021 and the Registrants Current Reports on Form 8-K filed with the
Commission on January 15, 2021, January
19, 2021, February 1, 2021, February
12, 2021, March 9, 2021, April
12, 2021 and April 14, 2021 (not including Item 7.01 and Exhibit 99.1);
(c) The description of the Registrants common stock, which is contained in a registration statement on Form
8-A filed on September 18, 2020 (File No. 001-39536) under the Exchange Act, including any amendment or report filed for the purpose of updating such
description; and
(d) All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14
and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this
Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be
incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be
deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes
such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Dallas, Texas, on
May 11, 2021.
|
|
|
TAYSHA GENE THERAPIES, INC.
|
|
|
By:
|
|
/s/ RA Session II
|
|
|
RA Session II
|
|
|
President and Chief Executive Officer
|
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints RA Session II and Kamran
Alam, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or
stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to sign any registration statement for the same offering covered by this Registration Statement that is to be
effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and
Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite
and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said
attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and
on the dates indicated.
|
|
|
|
|
Name
|
|
Position
|
|
Date
|
|
|
|
/s/ RA Session II
RA Session II
|
|
President, Chief Executive Officer and Director (Principal Executive Officer)
|
|
May 11, 2021
|
|
|
|
/s/ Kamran Alam
Kamran Alam
|
|
Chief Financial Officer
(Principal Financial and Accounting Officer)
|
|
May 11, 2021
|
|
|
|
/s/ Sean P. Nolan
Sean P. Nolan
|
|
Chairman
|
|
May 11, 2021
|
|
|
|
/s/ Phillip B. Donenberg
Phillip B. Donenberg
|
|
Director
|
|
May 11, 2021
|
|
|
|
/s/ Paul B. Manning
Paul B. Manning
|
|
Director
|
|
May 11, 2021
|
|
|
|
/s/ Sukumar Nagendran, M.D.
Sukumar Nagendran, M.D.
|
|
Director
|
|
May 11, 2021
|
|
|
|
/s/ Kathleen Reape, M.D.
Kathleen Reape, M.D.
|
|
Director
|
|
May 11, 2021
|
|
|
|
/s/ Laura Sepp-Lorenzino, Ph.D.
Laura Sepp-Lorenzino, Ph.D.
|
|
Director
|
|
May 11, 2021
|
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Apr 2023 to Apr 2024